Compare · BIIB vs JSPR
BIIB vs JSPR
Side-by-side comparison of Biogen Inc. (BIIB) and Jasper Therapeutics Inc. (JSPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and JSPR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.01B, about 1352.3x JSPR ($23.7M).
- BIIB has been more active in the news (6 items in the past 4 weeks vs 5 for JSPR).
- BIIB has more recent analyst coverage (25 ratings vs 24 for JSPR).
- Company
- Biogen Inc.
- Jasper Therapeutics Inc.
- Price
- $215.99-0.35%
- $0.70-4.07%
- Market cap
- $32.01B
- $23.7M
- 1M return
- -
- +15.53%
- 1Y return
- -
- -74.55%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 24
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Jasper Therapeutics Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Latest BIIB
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
- LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Latest JSPR
- SEC Form 8-K filed by Jasper Therapeutics Inc.
- SEC Form PRE 14A filed by Jasper Therapeutics Inc.
- SEC Form 10-Q filed by Jasper Therapeutics Inc.
- Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Piper Sandler initiated coverage on Jasper Therapeutics with a new price target
- SEC Form 4 filed by Director Wiggans Thomas G
- SEC Form 4 filed by Director Emster Kurt Von
- SEC Form 4 filed by Director Lucas Svetlana
- SEC Form 4 filed by Director Crutcher Patrick J
- SEC Form 4 filed by Director Shizuru Judith Anne